Annovis Bio 

Yahoo Finance • 3 days ago

Annovis Bio Regains NYSE Compliance Ahead Of 18-Month Cure Period

(RTTNews) - Annovis Bio, Inc. (ANVS), a clinical-stage biotechnology company, on Tuesday announced that it regained compliance with the New York Stock Exchange (NYSE) continued listing standards. Notably, the firm has regained full complia... Full story

Yahoo Finance • 10 days ago

Annovis Bio slips after pricing $15M equity offering

Annovis Bio (ANVS [https://seekingalpha.com/symbol/ANVS]) shares fell over -7% on Wednesday after the biotechnology company priced an offering to raise approximately $15M. The offering [https://seekingalpha.com/pr/20522328-annovis-announc... Full story

Yahoo Finance • 2 months ago

Annoivs Bio Launches $10M Underwritten Offering

(RTTNews) - Annovis Bio, Inc. (ANVS) announced a $10 million underwritten public offering of common stock and accompanying warrants. The offering is expected to provide additional capital to support the company's ongoing clinical programs... Full story

Yahoo Finance • 2 months ago

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative d... Full story

Yahoo Finance • 2 months ago

The Credibility Filter Wall Street Uses to Sort Biotech Winners

VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid or late stage clinic... Full story

Yahoo Finance • 2 months ago

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative d... Full story

Yahoo Finance • 6 months ago

Annovis Announces Two Presentations at the CTAD 2025 Conference

MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer... Full story

Yahoo Finance • 6 months ago

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

MarketNewsUpdatesNews Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer focus on preventive and longevity-focu... Full story

Yahoo Finance • 7 months ago

Annovis Bio announces $3.4 million registered direct offering of common stock priced at-the-market under the NYSE rules

* Annovis Bio(NYSE:ANVS [https://seekingalpha.com/symbol/ANVS]) said on Monday it has entered into definitive agreements for a registered direct offering of 1,670,732 shares of common stock at $2.05 per share, the closing price on the NY... Full story

Yahoo Finance • 7 months ago

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer... Full story

Yahoo Finance • 8 months ago

Annovis launches $6 million registered direct offering

* Annovis Bio (NYSE:ANVS [https://seekingalpha.com/symbol/ANVS]) has entered into definitive agreements for the purchase of an aggregate of 4M shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.... Full story

Yahoo Finance • 8 months ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock

MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer... Full story

Yahoo Finance • 8 months ago

Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment

MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer... Full story

Yahoo Finance • 8 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer

MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheime... Full story

Yahoo Finance • 8 months ago

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

MALVERN, Pa., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheime... Full story

Yahoo Finance • 9 months ago

Annovis Bio appoints CEO as acting CFO following executive resignation

Annovis Bio, Inc. (NYSE:ANVS) announced the upcoming resignation of Andrew Walsh, Vice President of Finance and Principal Financial Officer, effective August 22. According to a company statement based on a filing with the Securities and Ex... Full story

Yahoo Finance • 10 months ago

Annovis Bio (NYSE:ANVS) Reports Narrower Q2 2025 Loss, Advances Alzheimer's and Parkinson's Trials

Annovis Bio Inc. (NYSE:ANVS [https://www.chartmill.com/stock/quote/ANVS]) reported its second-quarter 2025 financial results, posting a net loss per share of $0.32, which was narrower than the analyst consensus estimate of a $0.41 loss. Th... Full story

Yahoo Finance • 11 months ago

Annovis Bio receives NYSE approval for compliance plan

* Annovis Bio (NYSE:ANVS [https://seekingalpha.com/symbol/ANVS]) received NYSE acceptance of its compliance plan regarding minimum market capitalization and stockholders' equity. * The company has 18 months from March 26, 2025, to rega... Full story

Yahoo Finance • 11 months ago

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the Company), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s... Full story

Yahoo Finance • 12 months ago

Annovis to Host Webinar and Live Q&A on June 24, 2025

MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD... Full story